PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.92%
Revenue growth of 0.92% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
3.15%
Gross profit growth 50-75% of Healthcare median of 6.23%. Guy Spier might worry about insufficient cost control or weaker pricing.
32.84%
EBIT growth exceeding 1.5x Healthcare median of 3.03%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
28.75%
Operating income growth exceeding 1.5x Healthcare median of 2.88%. Joel Greenblatt would see if unique processes drive exceptional profitability.
25.93%
Net income growth exceeding 1.5x Healthcare median of 2.24%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
25.93%
EPS growth exceeding 1.5x Healthcare median of 6.03%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
25.93%
Diluted EPS growth exceeding 1.5x Healthcare median of 6.06%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
142.00%
10Y CAGR of 142.00% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
46.86%
5Y CAGR of 46.86% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
31.11%
3Y CAGR of 31.11% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
182.37%
Net income/share CAGR exceeding 1.5x Healthcare median of 33.14% over a decade. Joel Greenblatt might see a standout compounder of earnings.
44.64%
5Y net income/share CAGR 1.25-1.5x Healthcare median. Mohnish Pabrai would check that top-line growth and share count management both contribute.
51.81%
3Y net income/share CAGR > 1.5x Healthcare median of 19.88%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
304.14%
Equity/share CAGR of 304.14% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
79.56%
5Y equity/share CAGR of 79.56% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
35.29%
Positive short-term equity/share CAGR while Healthcare is negative. Peter Lynch finds a relative advantage vs. sector-level slowdown.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
62.50%
3Y dividend/share CAGR of 62.50% while Healthcare is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
-1.61%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-6.17%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-2.56%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
2.19%
Positive BV/share change while Healthcare median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
11.12%
Slightly rising debt while Healthcare median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
No Data
No Data available this quarter, please select a different quarter.
-1.84%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.